<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03260153</url>
  </required_header>
  <id_info>
    <org_study_id>CBS-ICH</org_study_id>
    <nct_id>NCT03260153</nct_id>
  </id_info>
  <brief_title>Deproteinised Calf Blood Serum Injection for the Treatment of Acute Intracerebral Hemorrhage</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Stroke Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of Deproteinised Calf&#xD;
      Blood Serum Injection in alleviating perihematomal edema (PHE) and secondary brain injury, as&#xD;
      well as neurologic deficits in patients with acute intracerebral hemorrhage (ICH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study hypothesized that administration of Deproteinised Calf Blood Serum Injection would&#xD;
      alleviate PHE and secondary brain injury, thus improving clinical outcomes in patients with&#xD;
      ICH. The investigators will enroll 60 acute supratentorial ICH patients. Patients will be&#xD;
      assigned randomly to receive either Deproteinised Calf Blood Serum Injection or placebo&#xD;
      treatment, which is blinded to evaluator and patients. All patients in the study will receive&#xD;
      standard care treatment and clinical, diagnostic, laboratory, safety, and follow-up&#xD;
      evaluations. Blood will be drawn and brain MRI will be done in different time course.&#xD;
      Follow-up evaluations, including National Institute of Health stroke scale(NIHSS), Stroke&#xD;
      impact scale , Glasgow Coma Scale ,Barthel index score and modified Rankin scale assessments,&#xD;
      will be done periodically until 90 days after onset.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2017</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of cytotoxic and vasogenic edema on day 3 and day 7-10 (MRI evaluation)</measure>
    <time_frame>day 3, day 7-10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of vasogenic edema on day 14 (CT evaluation)</measure>
    <time_frame>day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of the biomarkers（MMP3、MMP9、TNF-α、IL-6、CRP） in the peripheral blood on different time course.</measure>
    <time_frame>at admission, day 3，day 3-7，day 14，day 30, day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome evaluated by Glasgow Coma Scale(GCS)scores.</measure>
    <time_frame>at admission, day 14， day 30， day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome evaluated by NIH Stroke Scale(NIHSS)scores.</measure>
    <time_frame>at admission, day 14， day 30， day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome evaluated by Barthel Index(BI) scores.</measure>
    <time_frame>day 14， day 30， day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome evaluated by Modified Rankin Scale(mRS)scores.</measure>
    <time_frame>at admission, day 14， day 30， day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome evaluated by Stroke Impact Scale (SIS) scores.</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Deproteinised Calf Blood Serum Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Chloride Physiological Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deproteinised Calf Blood Serum Injection</intervention_name>
    <arm_group_label>Deproteinised Calf Blood Serum Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Sodium Chloride)</intervention_name>
    <arm_group_label>Sodium Chloride Physiological Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of spontaneous intracerebral hemorrhage(sICH)&#xD;
&#xD;
          2. Bleeding into deep gray matter (basal ganglionic and thalamus), and the amount of&#xD;
             bleeding between 5 and 30 ml;&#xD;
&#xD;
          3. Age between 18 and 80 years;&#xD;
&#xD;
          4. Presentation within 48 hours of symptom onset, and NCCT at 24 hours need to be done in&#xD;
             patients presenting within 24 hours of symptom onset in order to exclude hematoma&#xD;
             expansion.&#xD;
&#xD;
          5. Informed consent by patients or relatives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Â secondary ICH (secondary to trauma, tumor, vascular malformations, ischemic stroke&#xD;
             hemorrhagic transformation, etc.);&#xD;
&#xD;
          2. Glasgow Coma Score of 3-8 at admission;&#xD;
&#xD;
          3. Parenchymal hemorrhage with ventricle involved;&#xD;
&#xD;
          4. Patients with hematoma expansion; .&#xD;
&#xD;
          5. Planned surgery within 3 days of symptom onset;&#xD;
&#xD;
          6. Incompletely absorbed brain hematoma previously;&#xD;
&#xD;
          7. Prestroke modified Rankin score(mRS)&gt;1;&#xD;
&#xD;
          8. Patients with hemorrhagic disease or coagulation disorders;&#xD;
&#xD;
          9. Patients with severe liver and renal insufficiency;.&#xD;
&#xD;
         10. Patients with severe heart failure or other serious systemic diseases;&#xD;
&#xD;
         11. Patients with malignant tumors or ongoing anti-tumor therapy;&#xD;
&#xD;
         12. Patients with a history of dementia or mental disorders;&#xD;
&#xD;
         13. Pregnant or lactating women or those who has a recent fertility plan;&#xD;
&#xD;
         14. Any contraindications to MRI(such as cardiac pacemakers and other metal implants,&#xD;
             claustrophobia);&#xD;
&#xD;
         15. Any other neuroprotective has been applied before randomization;&#xD;
&#xD;
         16. Terminal patients whose life expectancy &lt;90 days;&#xD;
&#xD;
         17. Patients participating in other clinical trials 30 days prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xingquan Zhao, MD</last_name>
    <phone>8610-67098891</phone>
    <email>zxq@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tian Tan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingquan Zhao, MD</last_name>
      <phone>8610-67098891</phone>
      <email>zxq@vip.163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Xingquan Zhao</investigator_full_name>
    <investigator_title>Professor of Neurology and Stroke Center</investigator_title>
  </responsible_party>
  <keyword>Intracerebral Hemorrhage</keyword>
  <keyword>Perihematomal edema</keyword>
  <keyword>Deproteinised Calf Blood Serum Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

